New GERD Therapy Arrives in Indonesia, Doctors: Patients Need Not Despair
Gastroesophageal reflux disease (GERD) remains one of the most common digestive tract issues encountered in Indonesia. Amidst a growing need for effective management, therapeutic options for GERD patients have expanded with the arrival of a new generation of potassium-competitive acid blocker (P-CAB) medication.
The Chairman of the Indonesian Gastroenterology Association (PB PGI), Prof. Dr. dr. Ari Fahrial Syam, MMB, SpPD, K-GEolog, FACG, FACP, stated that GERD issues are not always resolved by currently available therapies. According to him, some patients continue to experience symptoms despite receiving treatment.
“Acid reflux disease in Indonesia is almost endemic, including GERD. Current medications can be said to ultimately treat 80 per cent of cases, while 20 per cent fail,” Ari remarked during the Indonesian Digestive Disease Week (IDDW) 2026 in Jakarta.
Therefore, he noted that the introduction of new therapeutic options represents a significant development, particularly for patients who have not achieved optimal results from previous treatments. One of the therapies newly launched in Indonesia is fexuprazan, a P-CAB class drug developed for the management of GERD.
The launch was conducted by PT Daewoong Pharmaceutical Indonesia alongside a scientific symposium on 18 September 2026 in Jakarta. Ari mentioned that fexuprazan has previously been used in South Korea and has undergone research involving Indonesian patients. The investigator-initiated trial involved approximately 130 patients across three hospitals in Jakarta.
“Clinical trials on Indonesian patients have been conducted and are working well,” said Ari.
Source: jawawa.id (https://jawawa.id/newsitem/new-gerd-therapy-arrives-in-indonesia-doctors-patients-need-not-despair-1790038510)
Originally published by Republika (https://ameera.republika.co.id/berita/tlqp84328/terapi-baru-gerd-hadir-di-indonesia-dokter-pasien-tak-perlu-putus-asa), translated from Indonesian